Literature DB >> 11013646

Factors implicated in deaths from subarachnoid haemorrhage: are they avoidable?

P J Hutchinson1, H M Seeley, P J Kirkpatrick.   

Abstract

The major causes of death following subarachnoid haemorrhage are the effects of the initial bleed, aneurysmal rebleeding and delayed cerebral ischaemia. Although in many cases the causes are unavoidable, in others they are potentially preventable. By conducting a Regional Audit of patients who have died from subarachnoid haemorrhage, we have attempted to quantify these concerns. The medical records and CT scans of 200 patients who died from subarachnoid haemorrhage in hospitals in the East Anglian Region over a 5-year period were analysed, with particular regard to the identification of potentially avoidable factors, including radiologically confirmed rebleeding, marked hydrocephalus, and poor fluid and electrolyte resuscitation. Thirty-three patients presented with World Federation of Neurosurgical Societies (WFNS) Grade V with fixed pupils. These patients were deemed unsalvageable. Of the remainder, 106 were good grade (WFNS I-III) at initial presentation, 77 (73%) of whom died as a result of rebleeding (mean 10.4 days post-bleed) indicating delays in transfer and definitive treatment. Of the 61 poor grade patients (WFNS IV and V with reactive pupils) marked hydrocephalus occurred in 15 (25%) and poor resuscitation in 37 (61%). These were considered contributing factors to their poor clinical condition. Rebleeding was the main cause of death in the good grade patients, and correctable factors were identified which are known to contribute to a poor clinical condition in poor grade patients. The need for more rapid and active clinical intervention is indicated.

Entities:  

Mesh:

Year:  1998        PMID: 11013646     DOI: 10.1080/02688699845492

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  8 in total

1.  Subarachnoid haemorrhage and intracranial aneurysms: what neurologists need to know.

Authors:  P J Kirkpatrick
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-09       Impact factor: 10.154

Review 2.  Supply and demand of organs for donation.

Authors:  Gilbert Park
Journal:  Intensive Care Med       Date:  2003-11-29       Impact factor: 17.440

3.  Timing of surgery for supratentorial aneurysmal subarachnoid haemorrhage: report of a prospective study.

Authors:  N Ross; P J Hutchinson; H Seeley; P J Kirkpatrick
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

4.  Long-term domain-specific improvement following poor grade aneurysmal subarachnoid hemorrhage.

Authors:  J Mocco; Evan R Ransom; Ricardo J Komotar; Paulina B Sergot; Noeleen Ostapkovich; J Michael Schmidt; Kurt T Kreiter; Stephan A Mayer; E Sander Connolly
Journal:  J Neurol       Date:  2006-10-24       Impact factor: 4.849

5.  Clinical observation of the time course of raised intracranial pressure after subarachnoid hemorrhage.

Authors:  Yuhua Lv; Dayan Wang; Jin Lei; Ge Tan
Journal:  Neurol Sci       Date:  2015-01-22       Impact factor: 3.307

6.  External ventricular drainage response in poor grade aneurysmal subarachnoid hemorrhage: effect on preoperative grading and prognosis.

Authors:  Evan R Ransom; J Mocco; Ricardo J Komotar; Deshdeepak Sahni; Jennifer Chang; David K Hahn; Grace H Kim; J Michael Schmidt; Robert R Sciacca; Stephan A Mayer; E Sander Connolly
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

7.  Subarachnoid hemorrhage: management considerations for COVID-19.

Authors:  Eric J Panther; Brandon Lucke-Wold
Journal:  Explor Neuroprotective Ther       Date:  2022-03-02

8.  Treatment during cerebral vasospasm phase-complication association and outcome in aneurysmal subarachnoid haemorrhage.

Authors:  Isabel C Hostettler; Kornelia Kreiser; Maria Wostrack; Bernhard Meyer; Nicole Lange; Nina Schwendinger; Dominik Trost; Samira Frangoulis; Theresa Hirle; Jens Gempt
Journal:  J Neurol       Date:  2022-06-22       Impact factor: 6.682

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.